Biorestorative Therapies Stock Set to Reverse Split on Tuesday, September 8th (NASDAQ:BRTX)

Shares of Biorestorative Therapies, Inc. (NASDAQ:BRTX) are scheduled to reverse split before the market opens on Tuesday, September 8th. The 1-20 reverse split was recently announced. The number of shares owned by shareholders will be adjusted after the market closes on Monday, September 7th.

Biorestorative Therapies Stock Performance

BRTX opened at $0.14 on Friday. The stock’s 50 day moving average price is $0.27 and its 200-day moving average price is $0.28. Biorestorative Therapies has a one year low of $0.14 and a one year high of $1.73. The stock has a market cap of $3.66 million, a price-to-earnings ratio of -0.13 and a beta of 0.83.

Analysts Set New Price Targets

Separately, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Biorestorative Therapies in a research report on Monday, August 24th. One analyst has rated the stock with a Sell rating, According to data from MarketBeat.com, the company presently has an average rating of “Sell”.

Institutional Investors Weigh In On Biorestorative Therapies

Several large investors have recently added to or reduced their stakes in the stock. Virtu Financial LLC grew its stake in Biorestorative Therapies by 102.4% in the 3rd quarter. Virtu Financial LLC now owns 24,351 shares of the company’s stock worth $35,000 after acquiring an additional 12,319 shares in the last quarter. DRW Securities LLC purchased a new position in shares of Biorestorative Therapies during the fourth quarter worth approximately $55,000. Finally, Citadel Advisors LLC bought a new stake in shares of Biorestorative Therapies during the third quarter valued at approximately $152,000. 69.38% of the stock is owned by hedge funds and other institutional investors.

Biorestorative Therapies Company Profile

Biorestorative Therapies Inc (NASDAQ: BRTX) is a clinical-stage biopharmaceutical company focused on the development and commercialization of regenerative tissue therapy products. The company leverages a proprietary universal allogeneic cell technology platform to create high-potency cell therapy candidates designed to promote tissue repair, reduce inflammation and accelerate healing in areas damaged by disease or medical treatment.

Its lead development program targets radiation-induced oral mucositis (RIOM), a painful and dose-limiting side effect experienced by head and neck cancer patients undergoing radiotherapy.